University of Minnesota wordmark College of Pharmacy logo
Courses Phar 6122

 

ekgcircle3.gif (1164 bytes) Lecture Outlines: Diseases/Syndromes
Hyperlipidemia
 
Pathophysiology of the Atherosclerotic Process
Classification of Hyperlipidemia

General Approach to Treatment
NCEP Goals and Targets 

Risk Factors for ASCVD
Dietary Considerations

Drug Therapy
Special Considerations

Misc. Current Issues

Selected Studies
Example Exam Question
References
LFT Monitoring
SPECIAL CONSIDERATIONS
1. CRP Levels.  What is the deal?

2. Other disease states

  1. Metabolic Syndrome
  2. Nephrotic Syndrome
  3. Chronic renal failure
  4. Hypothyroidism (deal with the thyroid problem first and the lipid issue may correct itself)
  5. Hypertension (carefully select your antihypertensive agents for patients with co-existing hyperlipidemia)
3. Concomitant medications and their effect on serum lipids (JAMA 267:7 961-8. 1992)
Drug Total Cholesterol LDL-C HDL-C TRG
Diuretics + 7% +10-20% NS +25-50%
Beta-Blockers:
Non-Selective
Selective
ISA Activity
NS
0/+
NS
NS
??
NS
-13-14%
??
+9%
+20-50%
+20-50%
+4-32%
ACE-I NS NS NS NS
CCB's NS NS NS NS
Steroids +8-17% + +36-68% +
Alpha-Blockers -4% -10% +18% =7%

 

 

[Phar 6122 Homepage] [College of Pharmacy Homepage] [University of Minnesota Homepage]

 

The University of Minnesota is an equal opportunity educator and employer.

The views and opinions expressed in this page are strictly those of the page author. The contents of this page have not been reviewed or approved by the University of Minnesota.

©1997 by the Regents of the University of Minnesota
Last updated: February 12, 2003
Course Director: Robert J. Straka
Maintained by: Webmaster